Table 3.
The prognostic and diagnostic value of miR-1301.
| Tumor type | Expression pattern | Sample size | Prognostic value | Prognosis of patients with high/low miR-1301 level | Diagnostic value | Clinicopathological characteristics | Ref. |
|---|---|---|---|---|---|---|---|
| NSCLC | Upregulation | 124 patients | Independent prognostic factor for the overall survival | Poor | – | Positively related to the advanced TNM stages and lymph node metastasis | (3) |
| PTC | Downregulation | 70 patients | – | – | sensitivity = 59.3% specificity = 98.1% |
Negatively related to the advanced T and N stages | (5) |
| CRC | Downregulation | 113 patients | – | – | – | Negatively related to the advanced TNM stages and distant metastasis | (4) |
| Glioma | Downregulation | 184 patients | Independent prognostic factor for the overall survival and disease-specific survival | Poor | – | Negatively related to the high WHO grade, low KPS, and large tumor size | (2) |
| OS | Downregulation | 65 patients | Prognostic factor for the overall survival | Poor | – | Negatively related to the advanced TNM stages and distant metastasis | (6) |
NSCLC, Non-small cell lung cancer; PTC, papillary thyroid carcinoma; CRC, colorectal cancer; OS, osteosarcoma.